NGL Fine Chem Ltd's Q3FY25 Quarter Results
- 08 Feb 2025
Result Summary
- NGL Fine Chem Ltd reported a 9.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a decline of 2.9%.
- Its expenses for the quarter were up by 2.8% QoQ and 13.5% YoY.
- The net profit decreased 87.0% QoQ and decreased 87.2% YoY.
- The earnings per share (EPS) of NGL Fine Chem Ltd stood at 2.1 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 88.97 | 98.60 | 91.63 | -9.8% | -2.9% |
Total Expenses | 87.70 | 85.28 | 77.30 | 2.8% | 13.5% |
Profit Before Tax | 1.27 | 13.33 | 14.33 | -90.5% | -91.1% |
Tax | -0.01 | 3.52 | 4.30 | -100.3% | -100.2% |
Profit After Tax | 1.28 | 9.81 | 10.03 | -87.0% | -87.2% |
Earnings Per Share | 2.10 | 15.90 | 16.20 | -86.8% | -87.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
NGL Fine Chem Ltd is a leading player in the pharmaceutical industry, primarily focusing on the manufacture and supply of APIs (Active Pharmaceutical Ingredients). The company specializes in products related to veterinary and human healthcare, offering a diverse range of chemicals that cater to both domestic and international markets. As of the latest updates, there are no major developments available beyond the scope of this analysis period. NGL Fine Chem Ltd continues to operate within the pharmaceutical sector, a field characterized by constant innovation and regulatory oversight.
Revenue
During the third quarter of fiscal year 2025 (Q3FY25), NGL Fine Chem Ltd reported a total income of ₹88.97 crores. This figure represents a quarter-over-quarter (QoQ) decrease of 9.8% compared to the previous quarter (Q2FY25), where the total income stood at ₹98.60 crores. Additionally, the year-over-year (YoY) comparison with Q3FY24 shows a decline of 2.9% from ₹91.63 crores. This contraction in total income over both periods indicates a reduction in revenue generation, which may be attributed to various market factors affecting the pharmaceutical industry.
Profitability
For Q3FY25, the company reported a profit before tax (PBT) of ₹1.27 crores, marking a significant decrease of 90.5% QoQ from ₹13.33 crores in Q2FY25. Compared to the same quarter last year (Q3FY24), the PBT dropped by 91.1% from ₹14.33 crores. The tax expense for the quarter was negligible at -₹0.01 crores, a substantial decrease from ₹3.52 crores in Q2FY25 and ₹4.30 crores in Q3FY24. Consequently, the profit after tax (PAT) for Q3FY25 was ₹1.28 crores, reflecting an 87.0% QoQ decline from ₹9.81 crores and an 87.2% YoY decrease from ₹10.03 crores. The earnings per share (EPS) for the quarter also fell sharply to ₹2.10 from ₹15.90 in the previous quarter and ₹16.20 in the same quarter last year, illustrating the impact on shareholder returns.
Operating Metrics
The total expenses for Q3FY25 were reported at ₹87.70 crores, reflecting a QoQ increase of 2.8% from ₹85.28 crores in Q2FY25 and a YoY increase of 13.5% from ₹77.30 crores in Q3FY24. This rise in expenses, despite the decrease in total income, highlights a challenging operational quarter for the company. The financial data also shows a substantial drop in profitability metrics, with PBT, PAT, and EPS all experiencing significant declines both QoQ and YoY. These figures suggest that while income generation has waned, operating expenses have continued to rise, contributing to the overall reduction in profit margins for the company during the analyzed quarter.
